News

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.
Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...
The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst performance since 2008. Is the company in big trouble, or could this actually be a ...
Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...
In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.
Eli Lilly said it plans to submit the pill to the Food and Drug Administration for approval as a weight loss medication this ...